Aim. To assess laboratory markers of hemodynamic status in patients with moderate to severe COVID-19. Materials and Methods. Here we examined 15 COVID-19 16 critically ill patients. The control group consisted 20 healthy volunteers. levels endothelin-1, brain natriuretic peptide (BNP), N-terminal pro-brain (NT-proBNP) were measured by enzyme-linked immunosorbent assay. amounts nitrites (NO 2 ) ...

Carcinoid is a rare malignancy originating from enterochromaffin cells and is clinically characterized by flushing, diarrhea and bronchospasm, due to secretion of vasoactive substances. A dreaded complication is carcinoid heart disease, which mainly affects right cardiac chambers, resulting in thickened, immobile and retracted tricuspid and pulmonary valves. In the current report, a case of a 6...

Background Pro-B-Type Natriuretic Peptide (ProBNP), from which biologically active BNP and inactive amino-terminal BNP (NT-proBNP) are processed, has recently been reported to be elevated in patients with heart failure (HF). It remains to be shown in a large cohort study whether ProBNP circulates in normals, what factors influence ProBNP, and whether or not it is a sensitive biomarker for left ...

BACKGROUND The Zwolle Risk Score (ZRS) identifies ST-elevation myocardial infarction (STEMI) patients treated with primary percutaneous coronary intervention (PPCI) eligible for early discharge. We aimed to investigate whether baseline N-terminal pro-brain natriuretic peptide (NT-proBNP) is also able to identify these patients and could improve future risk strategies. METHODS AND RESULTS PPCI...

Background: Dyspnoeic in the emergency department with multiple co-morbidities is a diagnostic challenge. Approximately 15-20% of acute dyspneic Emergency Department due to ADHF (acute decompensated heart failure) are misdiagnosed. B-type peptide (BNP) and its amino-terminal fragment (NT-proBNP) accurately identify HF dyspnoeic patients. In general population dyspnoea, plasma pro-BNP concentrat...

Objectives: Although neurohormones have a well-established prognostic value in patients with chronic heart failure (CHF), little is known about this in CHF patients untreated with angiotensin-converting enzyme (ACE)-inhibitors, angiotensin-receptor blockers (ARBs) and beta-blockers. Methods: Baseline N-terminal pro atrial natriuretic peptide (NT-pro-ANP), N-terminal pro B-type natriuretic pepti...

B-type natriuretic peptide (BNP) and amino-terminal pro-BNP (NT-proBNP) are promising cardiac biomarkers that have recently been shown to be of diagnostic value in decompensated heart failure, acute coronary syndromes and other conditions resulting in myocardial stretch and volume overload. In view of the high prevalence of cardiac disorders in the intensive care unit, the experience of elevate...

Cardiac natriuretic peptides, especially amino terminal pro-Brain Natriuretic Peptide (NT-proBNP), are emerging as powerful circulating markers of cardiac function. However, the in vivo secretion and elimination (t1/2) of these peptides during acute volume overload have not been studied. We present the first report of the secretion and elimination of cardiac natriuretic peptides, based on decon...